PDGene

Gene overview of all published PD-association studies for APOE

Gene:

APOE (AD2; MGC1571; apoprotein)

View on ALSGene View on AlzGene View on MSGene View on SZGene

Protein:

apolipoprotein E (Alzheimer disease 2)

Chromosome:

19 (View: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 X Y MT)

Status:

Updated 27 November 2011

1. Case-Control Studies (by ethnic group)
				PD Cases				Normal Controls
Study	Population	Source	# Polys	# Subjects (% women)	DX	Onset Age (range)	Age (range)	# Subjects (% women)	Age (range)	Result
Caucasian
Ballering, 1997	Overlaps with Ghebremedhin, 2006	CL	2 (detail)	50 (-)	M	-	-	107 (-)	-	n.a.
Benjamin, 1994	UK	CL	2 (detail)	23 (-)	-	-	-	55 (-)	-	Negative
Blazquez, 2006	Spain	CL	2 (detail)	276 (41%)	C	64.2 + 11.3 (-)	71.1 + 10.2 (-)	212 (48%)	70.9 + 8 (-)	Positive
Bon, 1999	Overlaps with Ghebremedhin, 2006	CL	2 (detail)	50 (-)	N	-	-	96 (-)	-	n.a.
Buchanan, 2006	Australia	CL	2 (detail)	422 (43%)	C	59.9 + 10.4 (-)	66.9 + 9.8 (-)	387 (71%)	64.1 + 10.8 (-)	Positive
Cramer, 2009	USA	CL	2 (detail)	53 (36%)	C	-	65 + 10 (-)	54 (-)	55 + 15 (-)	Negative
Eerola, 2002	Finland	CL	2 (detail)	147 (41%)	C	-	67.2 (38-88)	137 (64%)	65.8 (37-87)	Negative
Egensperger, 1996	Overlaps with Grasbon-Frodl, 1999	CL	2 (detail)	20 (-)	M	-	76 + 6.2 (-)	54 (-)	71.2 + 9.5 (-)	n.a.
Egensperger, 1997	Overlaps with Grasbon-Frodl, 1999	CL	2 (detail)	23 (35%)	M	-	75.5 (-)	100 (54%)	74.3 (-)	n.a.
Engelborghs, 2003	Belgium	CL	2 (detail)	30 (43%)	C	68.5 + 7.7 (-)	75.4 + 6.7 (59-90)	189 (54%)	58.8 + 16.9 (19-95)	Negative
Ezquerra, 2008	Spain	CL	2 (detail)	138 (42%)	C	-	56 + 8.4 (-)	91 (56%)	67 + 9.2 (-)	Negative
Ferrarese, 2001	Italy	CL	2 (detail)	38 (-)	C	-	-	28 (-)	-	Negative
French Study Group, 1997	France	CL	2 (detail)	103 (46%)	C	57 (-)	65 (-)	387 (44%)	67 + 9 (-)	Positive
Fung, 2006	Overlaps with Simon-Sanchez, 2009 (USA)	CL	1 (detail)	267 (-)	C	-	-	270 (-)	68 (55-88)	n.a.
Gao, 2011	USA (PAGE)	PO	2 (detail)	786 (24%)	C	65.7 + 7.5 (-)	-	1537 (21%)	-	Positive
Ghebremedhin, 2006	Netherlands	CL	2 (detail)	108 (43%)	M	65.8 (-)	75.1 + 6.9 (55-89)	108 (43%)	75.1 + 6.9 (55-89)	Positive
Grasbon-Frodl, 1999	Germany	CL	2 (detail)	62 (53%)	M	-	70 (-)	53 (58%)	71 (-)	Negative
Hardy, 1994	UK	CL	2 (detail)	24 (-)	N	-	75 + 7 (-)	46 (-)	-	Negative
Harhangi, 2000	Netherlands	PO	2 (detail)	81 (63%)	C	-	75.8 + 7.8 (-)	4805 (55%)	69 + 8.6 (-)	Positive
Harrington, 1994	UK & Belgium	CL	2 (detail)	51 (49%)	N	-	77.7 + 7.1 (64-94)	58 (52%)	78.1 + 7.7 (60-91)	Negative
Helisalmi, 1996	Finland	CL	2 (detail)	15 (47%)	C	-	71 + 6 (-)	60 (47%)	69 + 8 (-)	Negative
Ibarreta, 1995	Spain	CL	2 (detail)	64 (-)	C	-	65.8 + 16 (44-90)	42 (-)	67.7 + 1.9 (52-90)	Negative
Khan, 2001	UK	CL	2 (detail)	305 (45%)	M	57 (-)	61 + 6 (-)	330 (47%)	63 + 7 (-)	Negative
Koller, 1995	USA	CL	2 (detail)	61 (38%)	C	-	67.4 + 7.9 (-)	78 (53%)	69.9 + 6.5 (-)	Negative
Kruger, 1999	Overlaps with Simon-Sanchez, 2009 (Germany)	CL	3 (detail)	236 (44%)	C	-	66.5 + 11 (-)	200 (-)	-	n.a.
Kruger, 2000	Overlaps with Schulte, 2003	CL	2 (detail)	191 (-)	C	-	-	293 (-)	-	n.a.
Kurz, 2009	Overlaps with Vefring, 2010 (Norway)	CL,PO	2 (detail)	95 (-)	M	-	-	73 (-)	-	n.a.
Maraganore, 2000	USA	CL	2 (detail)	139 (35%)	C	62 (31-82)	69 (39-91)	113 (65%)	72 (37-90)	Negative
Martinoli, 1995	Canada	CL	2 (detail)	10 (-)	N	-	69 (24-86)	243 (-)	-	Negative
Mattila, 1998	Finland	CL	2 (detail)	11 (45%)	M	-	71.9 + 6.8 (-)	59 (44%)	76 (-)	Negative
McCulloch, 2008	USA (Washington)	CL	2 (detail)	391 (26%)	C	-	67.3 (32-95)	293 (58%)	67.3 (30-93)	Positive
McCulloch, 2008	USA (Oregon)	CL	2 (detail)	172 (38%)	C	-	65.9 (39-87)	96 (55%)	67.8 (21-83)	Positive
McCulloch, 2008	USA (New York)	CL	2 (detail)	253 (35%)	C	-	68.1 (40-95)	214 (66%)	64.6 (34-94)	Positive
McCulloch, 2008	USA (Georgia)	CL	2 (detail)	116 (37%)	C	-	67.3 (40-97)	61 (67%)	68.5 (51-84)	Positive
Morris, 1996	Overlaps with Benjamin, 1994	CL	2 (detail)	11 (-)	M	-	-	99 (-)	-	n.a.
Oliveri, 1999	Italy	CL	3 (detail)	126 (43%)	C	58 + 10.4 (-)	65.8 + 9 (43-87)	119 (52%)	66.3 + 8.5 (50-92)	Negative
Pankratz, 2008	USA (PROGENI, GenePD)	CL	2 (detail)	857 (41%)	C	61.9 + 10.8 (-)	-	867 (60%)	54.8 + 13.1 (-)	Negative
Papapetropoulos, 2007	USA	CL	2 (detail)	118 (28%)	N	-	77 + 7.9 (-)	91 (53%)	79.1 + 12.8 (-)	Positive
Parsian, 2002	USA	CL	2 (detail)	285 (35%)	C	60 (22-82)	68 (-)	96 (35%)	62 + 14 (-)	Negative
Payami, 2009	Re-analysis of McCulloch, 2008	CL	2 (detail)	-	-	-	-	-	-	n.a.
Poduslo, 1995	USA	CL	2 (detail)	54 (-)	C	-	74.1 + 7.5 (-)	77 (-)	71.9 + 7.4 (-)	Negative
Rubinsztein, 1994	UK	CL	2 (detail)	34 (24%)	C	-	57 (-)	34 (-)	-	Negative
Schulte, 2003	Germany	CL	2 (detail)	457 (46%)	C	-	67.5 + 10.5 (-)	340 (48%)	72 + 4.3 (-)	Positive
Simon-Sanchez, 2009	USA, Germany (GWAS)	CL,PO	1 (detail)	1745 (45%)	C	55.8 (7-98)	-	4047 (50%)	-	Negative
Simon-Sanchez, 2009	USA (NINDS-GWAS)	CL	1 (detail)	931 (40%)	C	-	-	790 (58%)	-	Negative
St.Clair, 1997	UK	CL	2 (detail)	58 (33%)	M	-	78 (69-90)	47 (38%)	78 (67-91)	Negative
Troster, 2006	USA	CL	2 (detail)	62 (29%)	C	62.7 (-)	68.6 (-)	146 (51%)	71.5 + 7.2 (-)	Positive
Vefring, 2010	Norway	CL,PO	2 (detail)	203 (41%)	C	-	68.2 + 9.1 (-)	187 (47%)	66.2 + 9.6 (-)	Negative
Whitehead, 1996	Ireland	PO	2 (detail)	189 (35%)	C	45.6 + 7.6 (-)	56.9 + 6.6 (-)	162 (38%)	58 + 7.1 (-)	Negative
Williams-Gray, 2009	UK	CL,PO	2 (detail)	528 (40%)	C	62.5 + 11.8 (-)	-	512 (52%)	-	Negative
Asian
Arai, 1994	Overlaps with Higuchi, 2000	CL	2 (detail)	49 (-)	-	-	-	24 (-)	-	n.a.
Galasko, 2002	USA (Guam)	CL	2 (detail)	11 (55%)	C	63.3 + 3.3 (-)	68.4 + 9.8 (-)	403 (-)	-	Negative
Higuchi, 2000	Japan	CL	2 (detail)	140 (56%)	C	-	65.5 + 9.5 (-)	382 (69%)	74 + 5.6 (-)	Negative
Kiyohara, 2011	Japan	CL	2 (detail)	238 (62%)	C	-	68.5 + 8.6 (-)	296 (61%)	69.7 + 5.6 (-)	Positive
Pulkes, 2011	Thailand	CL	2 (detail)	155 (43%)	C	61.2 + 9.8 (40-82)	-	158 (-)	-	Trend
Ryu, 2010	Korea	CL	2 (detail)	234 (71%)	C	66.3 + 9.5 (-)	71.1 + 8.2 (-)	192 (49%)	72.2 + 4.9 (-)	Negative
Tang, 2002	China	CL	2 (detail)	68 (49%)	C	64.4 + 10.3 (-)	65.6 + 5.4 (43-76)	160 (53%)	55.8 + 15.4 (33-95)	Positive
Hispanic
Gallegos-Arreola, 2009	Mexico	CL	2 (detail)	105 (40%)	C	-	63 + 9 (-)	107 (56%)	50 + 14 (-)	Positive
Lopez, 2007	Mexico	CL	2 (detail)	229 (40%)	C	54.1 + 12.3 (-)	62.2 + 12.8 (-)	229 (40%)	63.9 + 11.2 (-)	Positive
Other/Mixed
Clark, 2003	USA	CO	1 (detail)	84 (56%)	C	-	67.8 + 10.3 (-)	458 (64%)	75.7 + 6 (-)	n.a.
Inzelberg, 1998	Israel	CL	1 (detail)	78 (22%)	C	-	72 + 12 (-)	93 (59%)	70 + 13 (-)	Trend
Marder, 1994	USA	CL	2 (detail)	57 (-)	C	-	71.2 (-)	44 (61%)	72.6 (-)	Negative

Contact us if you are an author of an association study regarding this gene and do not find your study in this table or find errors in the representation of your study details.

2. Family-Based Studies (by ethnic group)
				Affecteds				Unaffecteds
Study	Population	# Polys	# Families	# Subjects (% women)	DX	Onset Age (range)	Age (range)	# Subjects (% women)	Age (range)	Result
Caucasian
Li, 2004	USA & Australia	2 (detail)	658	972 (-)	C	-	-	873 (-)	-	Positive
Martinez, 2005	USA & Europe	2 (detail)		387 (-)	U	-	-	257 (-)	-	Positive

Contact us if you are an author of an association study regarding this gene and do not find your study in this table or find errors in the representation of your study details.

Source:  Source of case population -> “CL” (clinic-based), “PO” (population-based), or “CO” (community-based).
# Polys:  Number of polymorphisms tested per gene and per sample.
Onset Age and Age:  Mean or median age at onset or examination, respectively.
DX:  Criteria used to determine PD diagnosis -> "C" (clinical PD diagnosis), "N" (neuropathological PD diagnosis), "M" (mixed, i.e. PD sample contains both clinical and neuropathological cases), "U" (unknown).
Result:  Overall conclusion reached by authors of the original publication (“positive” usually indicates significant (P<0.05) association in at least one of the performed analyses, and “negative” indicates no evidence for significant association, while “trend” indicates results in between).
(-) :  Either no data provided or in case of overlap, data included in original study.